Description

Rilertinib Mesylate Product Specifications

 Overview & Mechanism

Rilertinib mesylate (Sanrisso®) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets activating mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC). It exhibits potent anti-tumor activity against EGFR-mutant NSCLC cell lines and tumor models.

 Research & Clinical Context

• China NMPA Approval (Feb 2025): Approved for patients with EGFR T790M mutation-positive advanced or metastatic NSCLC after progression on prior EGFR-TKI therapy.

• Phase III Trials: Demonstrated superior progression-free survival (PFS) compared to gefitinib in EGFR-mutant NSCLC patients.

 Research Applications

Ideal for:

• EGFR pathway and T790M-resistance mechanisms

• In vitro and in vivo NSCLC models

• Drug resistance and combination therapy studies

• Pharmacokinetic and pharmacodynamic profiling

 Handling & Storage

• Storage: Store at 20–25?°C, sealed and protected from light and moisture.

• Handling: Use appropriate laboratory personal protective equipment (PPE); avoid ingestion or inhalation.

 References

• NMPA approval announcement (Feb 19, 2025)

• Phase III trial results comparing rilertinib vs gefitinib

• Drug mechanism and development synopsis